Literature DB >> 15326069

The 1+1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias.

Dietmar Bänsch1, Frank Steffgen, Gerian Grönefeld, Christian Wolpert, Dirk Böcker, Ralph-Uwe Mletzko, Wolfgang Schöls, Karlheinz Seidl, Michael Piel, Feifan Ouyang, Stefan H Hohnloser, Karl-Heinz Kuck.   

Abstract

BACKGROUND: The tachycardia detection interval (TDI) in implantable cardioverter/defibrillators (ICDs) is conventionally programmed according to the slowest documented ventricular tachycardia (VT), with a safety margin of 30 to 60 ms. With this margin, VTs above the TDI may occur. However, longer TDIs are associated with an increased risk of inappropriate therapy. We hypothesized that patients with slow VTs (<200 bpm) may benefit from a long TDI and a dual-chamber detection algorithm compared with a conventionally programmed single-chamber ICD. METHODS AND
RESULTS: Patients with VTs <200 bpm were implanted with a dual-chamber ICD that was randomly programmed to a dual-chamber algorithm and a TDI of > or =469 ms or to a single-chamber algorithm with a TDI 30 to 60 ms above the slowest documented VT cycle length and the enhancement criteria of cycle length variation and acceleration. The primary combined end point was the number of all inappropriate therapies, VTs above the TDI, and VTs with significant therapy delay (>2 minutes). After 6 months, a crossover analysis was performed. Total follow-up was 1 year. One hundred two patients were included in the study. The programmed TDI was 500+/-36 ms during the dual-chamber phase and 424+/-63 ms during the single-chamber phase. For the primary end point (inappropriate therapies, VTs above the TDI, or VTs with detection delay), a moderate superiority of the dual-chamber mode was found: Mann-Whitney estimator=0.6661; 95% CI, 0.5565 to 0.7758; P=0.0040.
CONCLUSIONS: Dual-chamber detection with a longer TDI improves VT detection and does not increase the rate of inappropriate therapies despite a considerable increase in tachycardia burden.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15326069     DOI: 10.1161/01.CIR.0000140259.16185.7D

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

Review 1.  Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity.

Authors:  Oussama Wazni; Bruce L Wilkoff
Journal:  Nat Rev Cardiol       Date:  2010-04-20       Impact factor: 32.419

Review 2.  ICD programming.

Authors:  Mauro Biffi
Journal:  Indian Heart J       Date:  2013-12-20

3.  Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis.

Authors:  Emily P Zeitler; Gillian D Sanders; Kavisha Singh; Ruth Ann Greenfield; Anne M Gillis; Bruce L Wilkoff; Jonathan P Piccini; Sana M Al-Khatib
Journal:  Europace       Date:  2018-10-01       Impact factor: 5.214

Review 4.  Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management.

Authors:  Pow-Li Chia; David Foo
Journal:  Singapore Med J       Date:  2016-07       Impact factor: 1.858

Review 5.  Device Management in Heart Failure.

Authors:  Brett G Angel; Heath Saltzman; Luke S Kusmirek
Journal:  Curr Cardiol Rep       Date:  2017-09-25       Impact factor: 2.931

Review 6.  How to improve outcomes: should we put more emphasis on programming and medical care and less on patient selection?

Authors:  Laszlo Buga
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

7.  A new single chamber implantable defibrillator with atrial sensing: a practical demonstration of sensing and ease of implantation.

Authors:  Dietmar Bänsch; Ralph Schneider; Ibrahim Akin; Cristoph A Nienaber
Journal:  J Vis Exp       Date:  2012-02-28       Impact factor: 1.355

8.  Cardiac implantable electrical devices: bioethics and management issues near the end of life.

Authors:  Freddy M Abi-Samra
Journal:  Ochsner J       Date:  2011

9.  IEGM-online based evaluation of implantable cardioverter defibrillator therapy appropriateness.

Authors:  C Perings; T Korte; H-J Trappe
Journal:  Clin Res Cardiol       Date:  2006       Impact factor: 5.460

Review 10.  The role of remote monitoring in the reduction of inappropriate implantable cardioverter defibrillator therapies.

Authors:  J C J Res; D A M J Theuns; L Jordaens
Journal:  Clin Res Cardiol       Date:  2006       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.